Citation

Ruminski PG, Massa M, Strohbach J, Hanau CE, Schmidt M, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Shieh HS, Caspers N, Collins B, Grapperhaus M, Palmquist KE, Collins J, Baldus JE, Hitchcock J, Kleine HP, Rogers MD, McDonald J, Munie GE, Messing DM, Portolan S, Whiteley LO, Sunyer T, Schnute ME.: Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. J Med Chem, Volume 59 (1), 2016

Authors

Baldus JE, Carroll JN, Caspers N, Collins B, Collins J, Fletcher TR, Grapperhaus M, Hamper BC, Hanau CE, Hitchcock J, Kleine HP, Massa M, McDonald J, Messing DM, Munie GE, Palmquist KE, Portolan S, Rogers MD, Ruminski PG, Schmidt M, Schnute ME., Scholten JA, Shieh HS, Strohbach J, Sunyer T, Whiteley LO

Journal

J Med Chem

Year

2016

DOI

10.1021/acs.jmedchem.5b01434

PubMed

26653735

Machine-readable

REST APIRDF